Ann Williams, MD
Ophthalmology · Hammond, INNPI 1043216732
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 28.8% of the total. Reporting peaked in 2024 at $1,029 and has fallen 59.0% since, to $422 in 2025.
Across 135 payments — averaging $30.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$1K
- Harrow Eye, LLC$552
- Alcon$532
- AbbVie$396
- Rxsight Inc$280
- Kala Pharmaceuticals, Inc.$250
- plus $883 from 18 others
What the payments were for
- Food & beverage$3,96898%
- Gifts$962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 25 | $1,172 |
| Harrow Eye, LLC | 10 | $552 |
| Alcon | 14 | $532 |
| AbbVie(2 entities) | 24 | $396 |
| Rxsight Inc | 9 | $280 |
| Kala Pharmaceuticals, Inc. | 12 | $250 |
| Bausch & Lomb Americas Inc. | 7 | $218 |
| Tarsus Pharmaceuticals, Inc. | 4 | $114 |
| Beaver-visitec International, Inc. | 3 | $82 |
| Sun Pharmaceutical Industries Inc. | 5 | $68 |
| Dompe US, Inc. | 3 | $66 |
| Astellas Pharma US Inc | 4 | $63 |
| Mallinckrodt Hospital Products Inc. | 2 | $54 |
| Novartis | 2 | $33 |
| Ocular Therapeutix, Inc. | 2 | $30 |
| Thea Pharma Inc. | 1 | $23 |
| Sight Sciences, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Omeros Corporation | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $16 |
| Amgen | 1 | $14 |
| Eyepoint US, Inc. | 1 | $14 |
| Glaukos Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,064 in reported general payments places this provider in the 75th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 40 | $36,484 |
| LumiganBimatoprost | 52 | $25,019 |
| Cyclosporine | 32 | $15,448 |
| CombiganBrimonidine Tartrate/Timolol | 27 | $10,328 |
| Latanoprost | 592 | $6,389 |
| Travoprost | 27 | $5,883 |
| Timolol Maleate | 102 | $4,718 |
| Brimonidine Tartrate | 82 | $3,349 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $3,115 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 217 | $3,049 |
| Prednisolone Acetate | 85 | $2,475 |
| Dorzolamide Hcl | 43 | $790 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 48 | $434 |
| MoxifloxacinMoxifloxacin Hcl | 12 | $299 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 20 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $396 | $71,831119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Hammond
- Blake WilliamsHammond$6K
- Megan SilasHammond$5K
- Shamik BafnaLafayette$505K
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Omar DukarEvansville$43K
- Gerald RoperBatesville$34K
- Dwight SilveraEvansville$28K
- Michael OrrIndianapolis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.